8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): May 31, 2017

Heat Biologics, Inc.

(Exact name of registrant as specified in charter)

Delaware

(State or other jurisdiction of incorporation)

001-35994	26-2844103
(Commission File Number)	(IRS Employer Identification No.)

801 Capitola Drive

Durham, NC 27713

(Address of principal executive offices and zip code)

(919) 240-7133

(Registrant’s telephone number including area code)

N/A

(Former Name and Former Address)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company þ

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.þ 

Item 8.01. Other Events

Heat Biologics, Inc. (the “Company”) will be making several investor presentations over the next several weeks. In connection with the presentations, the Company intends to discuss the slide presentation attached as Exhibit 99.1 hereto, which is incorporated herein by reference.

The slide presentation attached as Exhibit 99.1 to this Report includes “safe harbor” language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained in the slide presentation or in the press release are “forward-looking” rather than historical.

The Company undertakes no duty or obligation to update or revise information included in this Report or any of the Exhibits.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Heat Biologics, Inc. investor presentation dated May 31, 2017

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated:  May 31, 2017	HEAT BIOLOGICS, INC.
	By:	/s/ Jeff Wolf
	Name:	Jeff Wolf
	Title:	Chairman, President and Chief Executive Officer

EXHIBIT INDEX

Exhibit Number	Description
99.1	Heat Biologics, Inc. investor presentation, dated May 31, 2017

EX-99.1

EXHIBIT 99.1

 NASDAQ:HTBX  May 31, 2017 

 This presentation includes statements that are, or may be deemed, ‘‘forward-looking statements’’ within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. They appear in a number of places throughout this presentation and include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ongoing and planned discovery and development of drugs targeting cancer, the strength and breadth of our intellectual property, our ongoing and planned preclinical studies and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, our ability to partner our product development, the degree of clinical utility of our products, particularly in specific patient populations, expectations regarding clinical trial data, our results of operations, financial condition, liquidity, prospects, growth and strategies, the length of time that we will be able to continue to fund our operating expenses and capital expenditures, our expected financing needs and sources of financing, the industry in which we operate and the trends that may affect the industry or us.  By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, and healthcare, regulatory and scientific developments and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in this presentation, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this presentation as a result of, among other factors, the factors referenced in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2016 and our quarterly report on Form 10-Q for the subsequent quarters (collectively, our “SEC Filings”). In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this presentation, they may not be predictive of results or developments in future periods. Any forward-looking statements that we make in this presentation speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this presentation, except as required by law.You should read carefully the factors described in the “Risk Factors” sections of our SEC Filings to better understand the risks and uncertainties inherent in our business.   2  Forward Looking Statements    

 Investment Opportunity  3            Favorable Safety Profile  TECHNOLOGIES  Multiple Platform  Signals in lung cancer with       CHECKPOINT Inhibitors  POTENTIAL BEST-IN-CLASS Activation of  Cancer Killing CD8+ T Cells  ROBUST Pipeline of  COMBINATION Therapies   Turning COLD Tumors HOT 

 4  Mission  Our Mission is to Activate CD8+ ”Killer” T cells to Turn “COLD” Tumors “HOT”  Cold  Hot    Our goal is to combine with checkpoint inhibitors and other immunotherapies to dramatically increase their effectiveness  

   What are COLD and HOT tumors?  5  Turning COLD Tumors HOT  Cold  Hot  COLD Tumors Tumors that have not been subject to robust CD8+ “Killer” T cell attackBiopsied tumors contain minimal CD8+ T cells    HOT TumorsTumors that have been subject to robust CD8+ “Killer” T cell attack Biopsied tumors are loaded with CD8+ T-cells  HOT tumors are associated with clinical response 

 Checkpoint inhibitors are dramatically changing the standard of care against a wide variety of cancers5 checkpoints approved to treat seven different cancers since 2014Additional checkpoints against new tumors expected later this yearCitibank, Goldman Sachs project checkpoints will be used to treat up to 60% of cancers, generating $30B – $40B revenues per year  6  The Checkpoint Revolution  But there is a problem…  Targets  Checkpoint  Company  Approved Indications  CTLA-4  Ipilumumab  BMS  Metastatic melanoma  PD-1  Nivolumab  BMS  Metastatic melanomaNSCLCBladder cancerHodgkin lymphomaRenal cell carcinoma  PD-1  Pembrolizumab  Merck  Metastatic melanomaNSCLCHead and neck  PD-L1  Atezolizumab  Genentech  Bladder cancer  PD-L1  Avelumab  Pfizer  Merkel cell carcinoma  Approved Checkpoint Inhibitors  Additional checkpoint approvals expected later this year 

 7  The Problem with Checkpoints        Survival  Traditional Therapies      Checkpoint Inhibitors Alone  Checkpoint inhibitors dramatically increase survival in patients with HOT tumors, but are largely ineffective in patients with COLD tumors  Potential for Checkpoint Inhibitors in Combination Therapies 

 Turning COLD tumors HOT  Focused on turning COLD tumors HOT to enhance the effectiveness of checkpoint therapy for the majority of patients who don’t respond to checkpoints alone    Checkpoint Inhibitor Monotherapy  Heat BiologicsCombination Therapy  Cold Tumor  Cold Tumor  Hot Tumor  Hot Tumor  Current Responders  Target Responders      Goal  Our goal is to dramatically increase the number of patients responding to checkpoints 

 Activates CD8+ T cells, a critical component of effective anti-cancer immunityActivated T cells invade tumor siteSimple once-a-week intradermal injectionWell-tolerated with combinationsClinical and preclinical data supports activity with ImPACT and checkpoint inhibitors  9  Checkpoint Combination Advantages  PD1/PD-L1CTLA-4Lag-3TIM-3Plus Others    Heat’s ImPACT Technology 

     Combination Therapies   10    T Cell Activation  ImPACT TherapyCell-Based Delivery of Multiple Antigens Activation of Patients’CD8+ “Killer” T Cells  ComPACT TherapyCell-Based Delivery ofMultiple Antigens Activation of Patients’CD8+ “Killer” T Cells  Co-Stimulation  Pelican PTX-25Monoclonal AntibodyPelican PTX-15Fusion Protein  Co-Stimulation to Enhance T cell Activation and Expansion  Checkpoint Inhibitors  PD1/PD-L1CTLA-4Lag-3TIM-3Plus Others    Unlocking the Body’s Natural Defenses with a Broad Range of Combination Therapies 

 PD1/PD-L1CTLA-4Lag-3TIM-3Plus Others    Pelican PTX-25Monoclonal AntibodyPelican PTX-15Fusion Protein      ImPACT / ComPACT Therapies  11    T Cell Activation  ImPACT TherapyCell-Based Delivery of Multiple Antigens Activation of Patients’CD8+ “Killer” T Cells  ComPACT TherapyCell-Based Delivery ofMultiple Antigens Activation of Patients’CD8+ “Killer” T Cells  Co-Stimulation to Enhance T cell Activation and Expansion  “Off-the-shelf” Cellular Therapies to Activate ”Killer” T Cells 

 ImPACT/ComPACT Manufacturing  12  Robust, Multi-Antigen T Cell Activation  Compare Using Our Proprietary Technology  Screen  ID Cell Line with Most Antigen OverlapTransfect with Activation Technology  Select  Scale-Up for Manufacturing by CMO  Scale-Up  Collect CancerCell Line & Patient Tissue Samples  Sample        Same process for ComPACT and ImPACTFrozen, fully-diluted single-dose vialFinal drug product: 1 million or 10 million cellsEasily scaled manufacturing  Low COG, off-the-shelf alternative to autologous therapies  

 ImPACT: Immune Pan-Antigen Cytotoxic Therapy  13                    ImPACT Cell    Cancer Killing T-Cell    ImPACT cells secrete antigens designed to specifically activate patient’s killer T-Cells  T-Cells circulate to destroy patient’s tumor  Cluster of five 0.1 mL intradermal injections  Activated cells EXPRESS chaperoned antigens  Activation Cell   CD8+ T Cell  Dendritic Cell  Chaperoned antigens activate dendritic cells which thenACTIVATE & PROLIFERATE CD8+ T cells  Dendritic Cell  ChaperonedAntigen   CD8+ T cells locate and ELIMINATE cancer cells  Tumor Cells  CD8+ T Cells 

 Heat Pipeline   14  Heat Biologics Corporate Model Deck  THERAPEUTIC VACCINES         HS-110(viagenpumatucel-L)  NSCLC  Phase II  ImPACT activation technology in combination with nivolumab and other checkpoint inhibitors TBA  HS-120  NSCLC  Preclinical  ComPACT activation technology in combination with checkpoint inhibitors TBA  CO-STIMULATORS        PTX-25  TBA  Preclinical  Humanized monoclonal antibody, functional agonist of human TNFRSF25  PTX-15  TBA  Preclinical  TL1A-Ig fusion protein, functional agonist of human TNFRSF25  Combination Therapies Designed to Activate the Body’s Own CD8+ T Cells to Fight Cancer  Met Clinical Endpoints to Progress to Phase 2 

   Objective  Evaluate objective response rate of HS-110 with a PD-1 checkpoint inhibitorCurrently 2nd line therapy or greater  Patient Population   Phase 1b expanded to Phase 2 in 1Q17 based upon efficacy  Secondary Endpoints  Safety and tolerability, immune response, overall survival and progression-free survival   Enrollment   5 – 10 U.S. sitesUp to 60 patientsPartnership with Yale Cancer Center on TIL analysis  HS-110 Phase 2 Lung Trial Design  15  HS-110 weekly intradermally for 18 weeks; nivolumab i.v. every other week until progression  HS-110 & PD-1 + other I-O tx  HS-110 & PD-1 + chemo  HS-110 & PD-1 + …  Phase 2  Possible additional arms    Low TIL at biopsy High TIL at biopsyBiopsy unevaluable   HS-110 & nivolumab   Enroll  Flexible trial design permits additional combinations 

   16  Activated Immune Response Correlates to Clinical Response  Key Findings    Source: HS-110 Ph 1b NSCLC data (left); HS-110 Ph 1b NSCLC data reported at World Lung Dec. 2016 (right)  Immune response to HS-110 observed in all 5 patients who had reduced tumorsPatients with no immune response to HS-110 did not have reduced tumorsTiming of immune responses to HS-110 corresponded to clinical responsesOf 5 patients enrolled in the low TIL cold tumor cohort, 3 (60%) exhibited substantial tumor reduction This exceeds the 10% response observed in low TIL patients treated with nivolumab alone   Overall Survival    Response at Week 10  High CD8+ TIL (≥10%)*  Baseline  Week 10  Source: March, 2017 Heat Biologics Trial Update   

 T Cell Tumor Infiltration  17  Clinical evidence that HS-110 is turning COLD tumors HOT“Killer” CD8+ T cells driven deep into tumors“Cold” tumors with no previous activation made highly active (”HOT”)Expression of PD-L1 increased with CD8+ T cell infiltration in some tumors  T Cell Infiltration Observed Deep Inside Tumors  Source: Data extracted from a patient as reported in Heat’s HS-110 Ph 1b NSCLC trial results, Dec 2016  CD8+ Staining  Baseline  Week 10    Conversion of Low TIL to High TIL After 10 Weeks onHS-110 & Nivolumab Combo 

 Positive Safety Signals  Over 1,000 doses administered to ~200 patientsOnly one patient ended treatment due to a non-serious adverse reaction*No systemic use of steroids required to treat reactionsNo serious adverse reactions No additive toxicities  18  1,000+ Doses – No Serious Adverse Reactions  Favorable Safety Profile To Date  *Represents the only patient of ~200 patients dosed who discontinued treatment for a vaccine-related adverse event  Immune Reaction*≤ Grade 3 toxicity  Injection Reactions  Week 1  Week 2 

 ComPACT Platform Technology  19  gp96-Ig  OX40L-Fc  The first potential dual-acting immunotherapy designed to deliver T cell activation and costimulation in a single product – combination therapy without additive costs     

     ComPACT Outperforms OX40 Monoclonal Antibodies in Preclinical Models   20  ComPACT leads to ~50% complete tumor rejection as compared to ~16% with OX40 agonist antibody combinations   

 T Cell Co-Stimulation  21  Heat Biologics Corporate Model Deck  CO-STIMULATORS        PTX-25  TBA  Preclinical  Humanized monoclonal antibody, functional agonist of human TNFRSF25  PTX-15  TBA  Preclinical  TL1A-Ig fusion protein, functional agonist of human TNFRSF25    Co-Stimulation  Pelican PTX-25Monoclonal AntibodyPelican PTX-15Fusion Protein  T Cell Co-stimulation to Enhance Immune Response Against Cancer 

 22    Heat has acquired 80% controlling interest in PelicanPelican will operate as a subsidiary in TexasPTX-25 - potential best-in-class co-stimulator Pre-clinical synergy with Heat’s ImPACT and checkpoint therapy$15.2M CPRIT Grant to fund clinical development  Heat Biologics Acquires Pelican Therapeutics 

 Emerging Target in T Cell Co-Stimulation  23  Many companies are pursuing co-stimulators with less specificity for CD8+ “memory” activation   Only Pelican is targeting TNFRSF25, an emerging target in immuno-oncology  Target   Lead mAb  Clinical Stage  Companies  Comments  4-1BB/4-1BBL  Urelumab, PF-05082566  Phase 1/2   BMSPfizer  Original phase II halted, now enrolling at lower doses  CD27  Varlilumab  Phase 2  BMSCelldex  mAb works by ADCC, no clinical evidence of agonism  OX40/OX40L  MEDI0562, MEDI6383  Phase 1  GenentechGSKMedimmune  Enrolling  GITR  TRX518  Phase 1  Merck  Enrolling  CD40/CD40L  CP-870893  Phase 1  Pfizer  Enrolling  HVEM/BTLA    Preclinical  BMS  IND Enabling  HVEM/LIGHT    Preclinical  BMS  IND Enabling  TNFRSF25/TL1A  PTX-25, PTX-15  Preclinical  HEAT/PELICAN  IND Enabling  None of these co-stimulators have advanced beyond phase 2 trials 

 24  Potential Best-in-Class Co-Stimulator  PTX-25 is a potential best-in-class T cell co-stimulator specific to “killer” CD8+ “memory” T cellsPre-clinical studies show advantages over competing T cell co-stimulator programs based on CD8+ T cell specificity$15.2 million New Company Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT)Propels PTX25 through a ~70-patient first-in-man clinical program Advance multiple products through preclinical development, and at least one through Phase I trials  Antigen-specific T cell proliferationIncreased effector cytokine production  Increased effector immune functionIncreased survival in preclinical models  Pre-clinical studies show advantages over competing T cell co-stimulator programs based on CD8+ T cell specificity 

 Pre-Clinical Data  25  Untreated (N=6)B16.F10-ova Only Control (N=6)OX40(ab) (N=8)ImPACT (N=8)ImPACT & OX40(ab) (N=8)ComPACT/OX40L (N=9)              Strong supporting pre-clinical data combining co-stimulators with Heat’s ImPACT/ComPACT therapies     Source: Fromm et al. Society for Immunotherapy of Cancer Annual Meeting, 2016                  CD8+ T Cell Activation  B16.F10 – Melanoma 

 PTX-25 Comparative Pre-Clinical Anti-Tumor Activity   26  TNFRSF25 agonism with murine mAb shows increased survival compared to other co-stimulators  Schreiber T. et al. SITC 2014  Comparative activity of OX40, GITR, 4-1BB and TNFRSF25 agonist mAbs in a long-established (9-day) B16-F10 melanoma model 

 Corporate Highlights  27  As of May 26, 2017; As reported as of March 31, 2017  Market Cap$25M1  Cash & Equiv.$11.1M2  NasdaqHTBX  Shares Outstanding35.6M  Shares Price$0.701  Grant Funds$15.2M 

 Heat Biologics Highlights  28    Lower COG Compared to Personalized Therapies    Phase II NSCLC Trial    Innovative drugs designed to turn COLD tumors HOT              Favorable Safety Profile  TECHNOLOGIES  Multiple Platform  Signals in lung cancer with       CHECKPOINT Inhibitors  POTENTIAL BEST-IN-CLASS Activation of  Cancer Killing CD8+ T Cells  ROBUST Pipeline of  COMBINATION Therapies 

   Cold  Hot    Turning COLD Tumors HOT 

 Appendix  30 

 Introducing gp96  *Schild, H. & Rammensee, H. Gp-96 – The Immune System’s Swiss Army Knife. Nature Immunology 2, 100-101 (2000)  “Molecular Warning System”  Natural biological process to deliver proteins (antigens) & gp96 adjuvant to our immune systemGp96 “chaperones” newly-created proteins to the cell membrane where they are released and embeddedActivates a cytotoxic T-cell response to the antigen it is carrying when cells die through necrosisEnables MHC I antigen cross-presentation to CD8+ T-cellsGp96 + protein are only naturally released via necrosisExposure of gp96 outside the cell activates an immune response to the antigen it is carrying Enables MHC I antigen cross-presentation specifically to CD8+ T-cellsAmong the most powerful adjuvants and the only adjuvant to show exclusive specificity to CD8+ (“killer”) T-cellsProvides long-term immunity against the infectious agent  Tethered to our cells with a “KDEL” leash          gp96  antigen  leash  Endoplasmic Reticulum  Cell Membrane    Antigen  31  The Immune System’s “Swiss Army Knife”* 

 ImPACT Therapy  Heat Biologics ImPACT technology reprograms cancer cells to continuously secrete their own antigens bound to heat shock protein gp96 to seek out and destroy a variety of tumours  Genetically modify tumor cells by “severing the leash” that binds the gp96 to the endoplasmic reticulum of the cell and replacing it with a sequence that pumps gp96 out of the cellEnables living cancer cells to “pump-out” their own surface antigens along with their gp96 chaperoneMimics necrotic cell deathActivates a powerful pan-antigen cytotoxic T-cell immune response  32  “Severing the Leash”  Heat Biologics ImPACT technology removes the leash that binds gp96 to the cell, replacing with a sequence that allows cells to continually secrete gp96 along with their “chaperoned” antigen      Cell Membrane       

 Expression of T cell Costimulators  Genomics Institute of the Novartis Research FoundationSu et al. PNAS 2004:101(16);6062-7  TNFRSF25 is preferentially expressed by human CD8+ T cells (red = high expression)  Compared to other T cell costimulators, TNFRSF25 is preferentially expressed on CD8+ T cells  33 

 Preferential CD8+ T cell Induction with TNFRSF25  Pre-clinical studies with murine agonist antibody shows preferential CD8+ T cell Induction; differentiation from other T cell costimulators  The frequency of antigen-specific memory CD4+ or memory CD8+ T cells were examined following treatment of mice with a vaccine alone, or in combination with OX40 or TNFRSF25 antibodiesTNFRSF25 preferentially ‘boosts’ CD8+ T cell immunity, whereas OX40 is preferential to CD4+ T cells  Schreiber et al. J Immunol 2012:189(7);3311-8  % AntigenSpecific Memory CD8+ T Cells    TNFRS25    OX40  34 

 Highlights from Pelican Pre-clinical Studies  mAb to TNFRSF25, drives the development of antigen-specific CD8+ T cells (this effect mimics TLIA, the natural monogamous ligand of TNFRSF25)mAb to TNFRSF25 results in costimulation and expansion of antigen-experienced memory T cells, both CD4+ and CD8+notable is a significantly enhanced effect on memory CD8+ T cellsCostimulation occurs only in the context of TCR recognition of antigenTNFRSF25 appears to have superior activity in stimulating memory CD8+ cells relative to OX40, 4-1BB and GITRAgonism with TNFRSF25 mAb leads to increases in effector cytokine and effector immune function, and increases survival in mouse modelsIn mouse melanoma models, TNFRSF25 mAb results in increased survival compared to agonism of OX40, GITR, 4-1BB with respective agonist mAbs  35